The Evaluation of the Efficacy and Safety of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment (MCI)

PHASE4CompletedINTERVENTIONAL
Enrollment

821

Participants

Timeline

Start Date

December 31, 2003

Primary Completion Date

March 31, 2007

Study Completion Date

March 31, 2007

Conditions
Memory Loss
Interventions
DRUG

Donepezil Hydrochloride

Subects will receive a starting dose of 5 mg orally. Dose-escalation from 5 mg to 10 mg will occur at the Week 9 Visit.

DRUG

Placebo

Subjects will receive matching placebo tablets.

Trial Locations (54)

Unknown

Albaster

Mesa

Peoria

Sun City

Tucson

Fresno

Garden Grove

Irvine

San Francisco

Denver

New Haven

Boynton Beach

Fort Meyers

Hollywood

Jacksonville

Melbourne

North Miami

Ocala

Sarasota

St. Petersburg

Tampa

Venice

West Palm Beach

Snellville

Chicago

Elkhart

New Orleans

Farmington Hills

Kalamazoo

Las Vegas

Kenilworth

Long Branch

Albany

Lexington

New York

Rochester

Staten Island

No. Charleston

Centerville

Cleveland

Toledo

Medford

Portland

Greensberg

Pittsburgh

Providence

Madison

Houston

San Antonio

Wichita Falls

Salt Lake City

Bennington

Charlottesville

Seattle

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Eisai Inc.

INDUSTRY